Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Mechanisms of action and antimicrobial activity of ceftobiprole.

Morosini MI, Díez-Aguilar M, Cantón R.

Rev Esp Quimioter. 2019 Sep;32 Suppl 3:3-10. Review.

2.

Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Dauner DG, Nelson RE, Taketa DC.

Am J Health Syst Pharm. 2010 Jun 15;67(12):983-93. doi: 10.2146/ajhp090285. Review.

PMID:
20516468
3.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.

Am J Clin Dermatol. 2008;9(4):245-54. Review.

PMID:
18572975
4.
5.

In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.

Pillar CM, Aranza MK, Shah D, Sahm DF.

J Antimicrob Chemother. 2008 Mar;61(3):595-602. doi: 10.1093/jac/dkm492. Epub 2008 Jan 23.

PMID:
18218646
6.
7.

Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Vidaillac C, Rybak MJ.

Pharmacotherapy. 2009 May;29(5):511-25. doi: 10.1592/phco.29.5.511. Review.

PMID:
19397461
8.

Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.

[No authors listed]

Drugs R D. 2006;7(5):305-11. Review.

PMID:
16922591
9.

Ceftobiprole: a new broad spectrum cephalosporin.

El Solh A.

Expert Opin Pharmacother. 2009 Jul;10(10):1675-86. doi: 10.1517/14656560903048967. Review.

PMID:
19527192
10.

Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.

Horn KS, Danziger LH, Rodvold KA, Glowacki RC.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):463-472. doi: 10.1080/17425255.2017.1303481. Epub 2017 Mar 17. Review.

PMID:
28264613
11.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

12.

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Bustos C, Del Pozo JL.

Infect Drug Resist. 2010;3:5-14. Epub 2010 Apr 22.

13.

Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.

Anderson SD, Gums JG.

Ann Pharmacother. 2008 Jun;42(6):806-16. doi: 10.1345/aph.1L016. Epub 2008 May 13. Review.

PMID:
18477729
14.

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Farrell DJ, Flamm RK, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2014 Jul;58(7):3882-8. doi: 10.1128/AAC.02465-14. Epub 2014 Apr 28.

15.

Ceftobiprole medocaril: a new generation beta-lactam.

Del Pozo JL, Patel R.

Drugs Today (Barc). 2008 Nov;44(11):801-25. doi: 10.1358/dot.2008.44.11.1264007. Review.

PMID:
19180259
16.

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K.

Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. Epub 2007 Apr 30.

17.

Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.

Scheeren TW.

Future Microbiol. 2015;10(12):1913-28. doi: 10.2217/fmb.15.115. Epub 2015 Nov 17. Review.

18.

Ceftobiprole - a case study.

Page MG.

Expert Opin Drug Discov. 2007 Jan;2(1):115-29. doi: 10.1517/17460441.2.1.115.

PMID:
23496040
19.

In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.

Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K.

Antimicrob Agents Chemother. 2010 Jan;54(1):116-25. doi: 10.1128/AAC.00642-09. Epub 2009 Nov 2.

20.

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-55. doi: 10.1016/j.diagmicrobio.2010.10.032.

PMID:
21353964

Supplemental Content

Support Center